LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid… 2023 · Cochrane Headline outcomes onlyOR 1.02 [0.91, 1.15]18 studies · 23183 participantsHigh